SEC Company Response from HEMAGEN DIAGNOSTICS INC (CIK 0000892822) — Sep 17, 2004

HEMAGEN DIAGNOSTICS INC (CIK 0000892822)
Date: Sept. 17, 2004 · CIK: 0000892822 · Accession: 0000892251-04-000862

View on Edgar

AI Filing Summary & Sentiment

Date

September 17, 2004

Author

Not clearly detected

Form

CORRESP

Company

HEMAGEN DIAGNOSTICS INC (CIK 0000892822)

Letter

RE: Hemagen Diagnostics, Inc. Schedule TO-1 Filed September 3, 2004 File No. 5-50367

Letter to SEC

Hemagen Diagnostics, Inc. 9033 Red Branch Road Columbia, Maryland 21045 (443) 367-5500

September 17, 2004

Securities and Exchange Commission

450 Fifth Street, N.W. Washington, DC 20549

Attention: Chris B. Edwards, Esq.

Ladies and Gentlemen:

Hemagen Diagnostics, Inc., (the “Company”) acknowledges:

• the Company is responsible for the adequacy and accuracy of the disclosure in the filings;

•

staff comments or changes to disclosure in response to staff comments in the filings reviewed by the staff do not foreclose the Commission from taking any action with respect to the filing; and

•

the Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Yours truly,

HEMAGEN DIAGNOSTICS, INC.

BY: /s/ William P. Hales ——————————————

William P. Hales

Chairman, President &

Chief Executive Officer

REAGENTS APPLICATIONS, INC.

BY: /s/ William P. Hales ——————————————

William P. Hales

Chairman and

Chief Executive Officer

Show Raw Text

CORRESP
1
filename1.htm

     Letter to SEC

Hemagen Diagnostics,
Inc.
9033 Red Branch Road
Columbia, Maryland 21045
(443) 367-5500

September 17, 2004

Securities and Exchange Commission

450 Fifth Street, N.W.
Washington, DC   20549

Attention: Chris B. Edwards, Esq.

RE:
Hemagen
Diagnostics, Inc.
Schedule TO-1 Filed September 3, 2004
File No. 5-50367

Ladies and Gentlemen:

        Hemagen
Diagnostics, Inc., (the “Company”) acknowledges:

  •
the
Company is responsible for the adequacy and accuracy of the           disclosure in the
filings;

•

staff comments or changes to disclosure in response to staff comments in the filings
reviewed by the staff do not foreclose the Commission from taking any action with respect
to the filing; and

•

the Company may not assert staff comments as a defense in any proceeding initiated by the
Commission or any person under the federal securities laws of the United States.

Yours truly,

HEMAGEN DIAGNOSTICS, INC.

BY: /s/ William P. Hales
——————————————

      William P. Hales

      Chairman, President &

      Chief Executive Officer

REAGENTS APPLICATIONS, INC.

BY: /s/ William P. Hales
——————————————

      William P. Hales

      Chairman and

      Chief Executive Officer

SecProbe.io